Left atrial appendage occlusion for atrial fibrillation and bleeding diathesis

BackgroundPatients with atrial fibrillation (AF) and likelihood of bleeding can undergo left atrial appendage occlusion (LAAO) as an alternative method of stroke prophylaxis. Short-term anti-thrombotic drugs are used postprocedure to offset the risk of device-related thrombus, evidence for this practice is limited.ObjectivesTo investigate optimal postimplant antithrombotic strategy in high bleeding-risk patients.MethodsPatients with AF and high-risk for both stroke and bleeding undergoing LAAO were advised their perioperative drug therapy by a multidisciplinary physician panel. Those deemed to be at higher risk of bleeding from anti-thrombotic drugs were assigned to minimal treatment with no antithrombotics or Aspirin-alone. The remaining patients received standard care (STG) with a 12 week course of dual-antiplatelets or anticoagulation postimplant. We compared mortality, device-related thrombus, ischemic stroke, and bleeding events during the 90 days postimplant and long-term. Event-free survival was assessed using Kaplan-Meier survival analysis, with logrank testing for statistical significance.ResultsSeventy-five patients underwent LAAO of whom 63 patients (84%) had a prior serious bleeding event. The 42 patients on minimal treatment were older (74.3 +/- 7.7 vs. 71.2 +/- 7.2) with higher HASBLED score (3.6 +/- 0.9 vs. 3.3 +/- 1.2) than the 33 patients having standard care. There were no device-related thrombi or strokes in either group at 90 days postprocedure; STG had more bleeding events (5/33 vs. 0/42, p = 0.01) with associated deaths (3/33 vs. 0/42, p = 0.05). During long-term follow-up (median 2.2 years), all patients transitioned onto no antithrombotic drugs (43 patients [61%]) or a single-antiplatelet (29 patients [39%]). There was no evidence of early minimal treatment adversely affecting long-term outcomes.ConclusionsShort-term anti-thrombotic drugs may not be needed after LAAO implant in patients with high bleeding risk and could be harmful. Larger, prospective studies would be warranted to test these findings. This retrospective data reports comparison of a minimal postprocedure anti-thrombotic strategy versus standard care anti-thrombotic strategy in a high bleeding risk population undergoing left atrial appendage occlusion (LAAO).It reports that there was significant increase in the combined endpoint of bleeding, device-related thrombus, and stroke after 90 days in the standard anti-thrombotic group.It reports safe outcomes on a subset of patients that safely had no antithrombotic therapy post-LAAO implant.image